MIT Scientist to Present at BIO 2015
MIT scientist Robert Langer will speak at BIO 2015 on a panel about venture capitalism in biotechnology.
Robert Langer, MIT scientist and professor, will be speaking on a panel at the BIO International Convention 2015. The panel, Thirty Years of Venture Capitalism in Biotechnology, will take place on June 15, 2015 at 12:30 pm EST and will feature discussions on the history of venture capitalism in biotechnology, how it has shaped the industry, and how it has changed over time. Langer, the 2014 winner of the Biotechnology Heritage Award, which is presented by the Chemical Heritage Foundation every year at BIO Convention, will be joined on the panel by two other winners of this award: Moshe Alafi (2015 winner), a venture capitalist in biotechnology, and Joshua Boger (2011 winner), an entrepreneur and co-founder of Vertex Pharmaceuticals.
For more information on BIO International Convention 2015, please visit BIO 2015. The convention will be held June 15 to June 18, 2015 in Philadelphia, PA at the Philadelphia Convention Center.
Source: BioTech Now
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
